[3] Determination of adenylyl cyclase catalytic activity using single and double column procedures

We previously showed that phorbol-12-myristate-13-acetate (PMA) mediates a robust PKC-dependent sensitization and desensitization of the highly homologous human Gs protein and adenylyl cyclase (AC)-linked D1 (hD1R) and D5 (hD5R) dopaminergic receptors, respectively. Here, we demonstrate using forskolin-mediated AC stimulation that PMA-mediated hD1R sensitization and hD5R desensitization is not associated with changes in AC activity. We next employed a series of chimeric hD1R and hD5R to delineate the underlying structural determinants dictating the subtype-specific regulation of human D1-like receptors by PMA. We first used chimeric receptors in which the whole terminal region (TR) spanning from the extracellular face of transmembrane domain 6 to the end of cytoplasmic tail (CT) or CT alone were exchanged between hD1R and hD5R. CT and TR swaps lead to chimeric hD1R and hD5R retaining PMA-induced sensitization and desensitization of wild type parent receptors. In striking contrast, hD1R sensitization and hD5R desensitization mediated by PMA are correspondingly switched to PMA-induced receptor desensitization and sensitization following the IL3 swap between hD1R and hD5R. Cell treatment with the PKC blocker, Gö6983, inhibits PMA-induced regulation of these chimeric receptors in a similar fashion to wild type receptors. Further studies with chimeras constructed by exchanging IL3 and TR show that PMA-induced regulation of these chimeras remains fully switched relative to their respective wild type parent receptor. Interestingly, results obtained with the exchange of IL3 and TR also reveal that the D1-like subtype-specific regulation by PMA, while fully dictated by IL3, can be modulated in a receptor conformation-dependent manner. Overall, our results strongly suggest that IL3 is the critical determinant underlying the subtype-specific regulation of human D1-like receptor responsiveness by PKC.

Herein, we investigate the differential D1 dopaminergic receptor (D1R) regulation by G protein-coupled receptor kinase (GRK) 2 and 3 using two truncated receptors lacking the distal (Δ425) and distal–central (Δ379) cytoplasmic tail (CT) regions. We first show the association between D1R and GRKs in co-transfected cells and rat striatum. Our studies further indicate that deletion of distal CT region of D1R does not alter the association between receptor and GRK2. Meanwhile, removal of both distal and central CT regions culminates in a drastic increase in the basal association between Δ379 and GRK2 relative to D1R and Δ425. Interestingly, CT truncations have no effect on the basal and DA-induced association of receptors with GRK3. Furthermore, we demonstrate that desensitization of D1R is considerably more robust in cells expressing GRK3. Notably, the robust GRK3-induced D1R desensitization is not attenuated by CT deletions. However, GRK2-induced Δ425 desensitization is not detectable whereas we unexpectedly find that Δ379 desensitization is similar to GRK2-induced D1R desensitization. GRK2 and GRK3-dependent desensitization of wild type D1R is not linked to differences in the extent of DA-induced receptor phosphorylation. Moreover, our studies show that GRK2-induced D1R phosphorylation is only modulated by deletion of distal CT region while distal and central CT regions control GRK3-induced D1R phosphorylation. Intriguingly, dopamine-induced Δ379 phosphorylation by GRK3 was significantly lower than receptor phosphorylation in cells harboring Δ379 alone or Δ379 and GRK2. Overall, our study suggests an intricate interplay between CT regions of D1R in differentially regulating receptor responsiveness by GRK2 and GRK3.

Dopamine D1 and D5 receptors are prototypical cell-surface seven-transmembrane (TM) G protein-coupled receptors (GPCRs) mediating elevation of intracellular cAMP levels. The high level of constitutive activity of D5 receptor mediating intracellular cAMP production is one of the functional hallmarks distinguishing the closely related D1-like dopaminergic subtypes (D1 and D5). D1-like subtypes share over 80% identity within their TM regions. Thus, D1 and D5 receptors can serve as unparalleled and useful molecular tools to gain structural and mechanistic insights into subtype-specific determinants regulating GPCR constitutive activation and inverse agonism. A method has been developed that relies on the use of transfected human embryonic kidney 293 cells with wild‐type (WT), epitope-tagged, chimeric, truncated, and mutant forms of mammalian D1 and D5 receptors using a modified DNA and calcium phosphate precipitation procedure. Receptor expression levels are quantified by a radioligand binding using [³H]-SCH23390, a D1-like selective drug. Regulation of ligand-independent and dependent activity of WT and mutated D1 and D5 receptors is determined by whole cell cAMP assays using metabolic [³H]-adenine labeling and sequential purification radiolabeled nucleotides over Dowex and alumina resin columns. Results on the regulation of D1 and D5 constitutive activity are presented here. Our studies indicate that dopamine-mediated D5 receptor stimulation in a dose-dependent manner is not always detectable, suggesting that D5 receptors can exist in a “locked” constitutively activated state. This “locked” constitutively active state of D5 receptor is not linked to aberrant high receptor expression levels or cell behavior, as D1 receptor function remains essentially unchanged in these cells. In fact, we show that phorbol ester treatment of cells harboring “locked” constitutively active D5 receptors abrogates constitutive activation of D5R to allow its stimulation by dopamine in a dose-dependent manner.

Bacterial protein toxins are powerful tools for elucidating signaling mechanisms in eukaryotic cells. A number of bacterial protein toxins, e.g. cholera toxin, pertussis toxin (PTx), or Pasteurella multocida toxin (PMT), target heterotrimeric G proteins and have been used to stimulate or block specific signaling pathways or to demonstrate the contribution of their target proteins in cellular effects. PMT is a major virulence factor of P. multocida causing pasteurellosis in man and animals and is responsible for atrophic rhinitis in pigs. PMT modulates various signaling pathways, including phospholipase Cβ and RhoA, by acting on the heterotrimeric G proteins Gα_q and Gα_12/13, respectively. Here we report that PMT is a powerful activator of G_i protein. We show that PMT decreases basal isoproterenol and forskolin-stimulated cAMP accumulation in intact Swiss 3T3 cells, inhibits adenylyl cyclase activity in cell membrane preparations, and enhances the inhibition of cAMP accumulation caused by lysophosphatidic acid via endothelial differentiation gene receptors. PMT-mediated inhibition of cAMP production is independent of toxin activation of Gα_q and/or Gα_12/13. Although the effects of PMT are not inhibited by PTx, PMT blocks PTx-catalyzed ADP-ribosylation of G_i. PMT also inhibits steady-state GTPase activity and GTP binding of G_i in Swiss 3T3 cell membranes stimulated by lysophosphatidic acid. The data indicate that PMT is a novel activator of G_i, modulating its GTPase activity and converting it into a PTx-insensitive state.

The first effects of 3,4-methylen-dioxy-metamphetamine (MDMA, “ecstasy”), on serotonin 1A (5-HT_1A) receptors in rat hippocampus were determined by means of [³H]-8-hydroxy-dipropylamino-tetralin ([³H]-8-OH-DPAT) and 5′guanosine-(γ-[³⁵S]-thio)triphosphate ([³⁵S]-GTPγS) binding as well as inhibition of forskolin (FK)-stimulated adenylyl cyclase (AC) activity. The study was completed by [³⁵S]-GTPγS functional autoradiography experiments carried out in frontal sections of rat brain, including the hippocampal region. Results showed that MDMA was either able to displace [³H]-8-OH-DPAT binding (K_i ≅ 500 nM) or to reduce the number of specific sites (B_max) without affecting K_d. The drug also failed to change the [³⁵S]-GTPγS binding or to inhibit AC velocity, underlying its behavior as a non-competitive 5-HT_1A receptor antagonist. Further, MDMA (1 or 100 μM), partially antagonized either [³⁵S]-GTPγS binding stimulation of the agonists 5CT and 8-OH-DPAT or the AC inhibition induced by 5CT and DP-5CT. However, in contrast to binding studies, in AC assays the amphetamine displayed an effect also on EC₅₀, always being less potent than the reference antagonist WAY100,635. In functional autoradiography, MDMA behaved either as a partial 5-HT_1A antagonist in limbic areas or, added alone, as an agonist, increasing the coupling signal presumably through 5-HT release from synapses. Interestingly, the selective 5-HT re-uptake inhibitor (SSRI) fluoxetine had no effect on MDMA [³⁵S]-GTPγS binding activation. This latter finding indicates that the amphetamine can release 5-HT via alternative mechanisms to 5-HT transporter binding, probably via membrane synaptic receptors or vesicular transporters. The release of other transmitters is not excluded. Therefore, our results encourage at extending the study of MDMA biochemical profiles, in the attempt to elucidate those amphetamine-induced pathways with a potential for neurotoxicity or psycho-stimulant activity.

Prostatic β-adrenoceptors inhibit α₁-adrenoceptor-stimulated contractility. This study examines the effects of β-adrenoceptor stimulation upon phenylephrine-induced elevations of intracellular Ca²⁺([Ca²⁺]_i) in human cultured prostatic stromal cells, and contractility of human prostatic tissue. Human cultured prostatic stromal cells were used for [³H]-cAMP accumulation studies or were loaded with 5-oxazolecarboxylic acid, 2-(6-(bis(2-((acetyloxy)methoxy)-2-oxoethyl)amino)-5-(2-(2-(bis(2-((acetyloxy)methoxy)-2-oxoethyl)amino)-5-methylphenoxy)ethoxy)-2-benzofuranyl)-, (acetyloxy)methyl ester (FURA-2AM, 10 μM) for Ca²⁺ imaging studies. The β-adrenoceptor agonist isoprenaline increased the accumulation of [³H]-cAMP (pEC₅₀ ± S.E.M. 6.58 ± 0.11) in human cultured prostatic stromal cells, an effect antagonized by the β₂-adrenoceptor antagonist (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol (ICI 118,551), but not by the β₁-adrenoceptor antagonist, atenolol. Isoprenaline (3 μM), the adenylyl cyclase activator, forskolin (20 μM) and the phosphodiesterase-4 inhibitor, rolipram (10 μM) inhibited the elevation of [Ca²⁺]_i elicited by phenylephrine (20 μM). The effect of isoprenaline could be blocked by ICI 118,551 (100 nM), the adenylyl cyclase inhibitor cis-N-(2-phenylcyclopentyl)-azacyclotridec-1-en-2-amine (MDL 12,330A, 20 μM) and the K_Ca channel blocker, iberiotoxin (100 nM), but not by atenolol (1 μM) or the K_ATP channel blocker, glibenclamide (3 μM). Agonists selective for β₁-(xamoterol and prenalterol), β₂-(procaterol and salbutamol) and β₃-((±)-(R^⁎, R^⁎)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid, BRL37344) adrenoceptors inhibited the elevation of [Ca²⁺]_i elicited by phenylephrine (20 μM) with a rank order of BRL37344 ≥ xamoterol ≥ isoprenaline > procaterol ≥ prenalterol > salbutamol. The xamoterol effect was reversed by ICI 118,551 (100 nM), but not by 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol (SR59230A, 100 nM) or atenolol (1 μM). The BRL37344 effect was reversed by SR59230A (100 nM), but not by atenolol (1 μM) or ICI 118,551 (100 nM). Both xamoterol and BRL37344 inhibited phenylephrine-induced tissue contractility. This study shows that both xamoterol and BRL37344 are effective inhibitors of phenylephrine-induced effects in human cultured prostatic stromal cells and in prostatic tissue.